-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Downgrades Novo Nordisk to Underweight, Maintains Price Target to $40

Benzinga·09/11/2026 11:39:26
語音播報
Morgan Stanley analyst Thibault Boutherin downgrades Novo Nordisk (NYSE:NVO) from Equal-Weight to Underweight and maintains the price target from $40 to $40.